Investigating the health effects of electronic nicotine delivery systems
Cardiopulmonary Toxicity of Electronic Nicotine Delivery Systems
This study is looking at how vaping affects heart and lung health, especially for young people, by checking what harmful chemicals are released from different e-liquids and devices, so everyone can better understand the risks involved.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11001192 on NIH RePORTER |
What this research studies
This research focuses on understanding the cardiopulmonary toxicity associated with electronic nicotine delivery systems (ENDS), which are commonly used by youth and young adults. The study aims to analyze how different e-liquid compositions and device types contribute to the generation of harmful volatile organic compounds (VOCs) like formaldehyde and acrolein. By examining the cardiovascular and pulmonary effects of e-cigarette aerosols under various conditions, the research seeks to provide essential data that could inform regulatory decisions by the FDA. Patients may benefit from a clearer understanding of the health risks associated with these products.
Who could benefit from this research
Good fit: Ideal candidates for this research include youth and young adults who use electronic nicotine delivery systems.
Not a fit: Patients who do not use electronic nicotine delivery systems or have no exposure to these products may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved safety regulations for electronic nicotine delivery systems, ultimately protecting public health.
How similar studies have performed: Previous research has indicated potential health risks associated with e-cigarettes, but this study aims to provide more specific insights into the cardiopulmonary effects, making it a novel approach.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Conklin, Daniel Joseph — University of Louisville
- Study coordinator: Conklin, Daniel Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.